Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D

In patients affected by chronic hepatitis because of HBV infection, long‐term suppressive therapy with nucleos(t)ides analogues in the HBeAg− patients has shown low effects on HBsAg titre (qHBsAg) decrease, and HBsAg loss is difficult to achieve. Thus, in this type of patients the main goals of antiviral therapy is the suppression of HBV‐DNA and ALT normalization.

[1]  H. Chan,et al.  Predictors of Treatment Response in Chronic Hepatitis B , 2009, Drugs.

[2]  C. Boucher,et al.  Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. , 2011, The Journal of infectious diseases.

[3]  Soon Sun Kim,et al.  Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B , 2011, Journal of medical virology.

[4]  S. Ahn,et al.  Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir , 2011, Hepatology.

[5]  M. Manns,et al.  Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients , 2010, Hepatology.

[6]  Xia-qiu Zhou,et al.  On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  P. Marcellin,et al.  HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment , 2010 .

[8]  D. Moradpour,et al.  [Management of chronic hepatitis B]. , 2010, Revue medicale suisse.

[9]  V. Wong,et al.  Surrogate end points and long-term outcome in patients with chronic hepatitis B. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  P. Marcellin,et al.  Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B , 2009, Hepatology.

[11]  T. Asselah,et al.  Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients , 2009, Hepatology.

[12]  Jörg Petersen,et al.  EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.

[13]  V. Wong,et al.  Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  Olga Angelopoulou,et al.  Prediction of Treatment-Related HBsAg Loss in HBeAg-Negative Chronic Hepatitis B: A Clue from Serum HBsAg Levels , 2007, Antiviral therapy.

[15]  M. Chevallier,et al.  Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. , 2005, Journal of hepatology.

[16]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .